The BMJH Sankalp Center for Paediatric Haematology Oncology has achieved JACIE certification, a landmark milestone for haematopoietic cell transplantation and cellular therapy in India. This certification ensures safe and effective care for children with life-threatening blood disorders.
Clínica Ruiz / Centro de Hematología y Medicina Interna has become the first program accredited through the FACT-JACIE Accreditation Program in Latin America for hematopoietic cell transplantation and cellular therapy. The accreditation recognizes 33 years of experience in HCT conducted in unique circumstances, including in a middle-in...
The new certification framework covers the full IEC therapy process, including patient selection, clinical care, and post-infusion monitoring. It emphasizes critical aspects unique to IEC therapies, such as chain-of-identity and recognition of therapy-specific toxicities.
European Society for Blood and Marrow Transplantation (EBMT) has achieved certification under ISO/IEC 27001:2022, demonstrating its commitment to protecting sensitive patient data. This milestone highlights EBMT's dedication to information security and operational excellence across its ecosystem, including the EBMT Registry.
The European Society for Blood and Marrow Transplantation has released its 2025 clinical practice recommendations for haematopoietic cell transplantation and CAR-T therapy. The report highlights the growing role of innovative therapies in transforming treatment paradigms, while emphasizing the importance of harmonizing practices across...
The EASYGEN consortium will develop a fully automated platform for manufacturing personalized cell therapies within days, accelerating patient access and reducing costs. EBMT is participating in the study examining current CAR-T treatment processes and contributing to patient education and advocacy efforts.
The 10th ITCTC Course will take place from 5-7 September 2025 at the University of Barcelona, featuring comprehensive education on haematopoietic cell transplantation and cellular therapies. Selected oral case presenters will receive travel grants to attend.
The GVHD Alliance has expanded into Europe under the leadership of the European Society for Blood and Marrow Transplantation (EBMT). This move aims to foster collaboration among healthcare professionals, patient advocacy groups, researchers, and policy leaders to improve care and access for patients living with Graft-versus-Host Diseas...
The EBMT has introduced an upgraded patient Registry database to improve data collection, retrieval, and analysis in haematopoietic cell transplantation (HCT) research. The new platform offers enhanced features for healthcare professionals and researchers to access clinical data effectively.
The EBMT has released a comprehensive guide to transplant and cell therapy nursing, providing nurses with essential information on transplant care and current research practices. The new edition includes updates on Covid-19 and a dedicated chapter on cell therapy nursing care.
A phase III trial demonstrated that combining Eltrombopag with standard immunosuppression increases response rates and reduces time to first response in patients with Severe Aplastic Anemia. The treatment was found to be safe and well-tolerated, with improved event-free survival.
The EBMT 2021 Scientific Programme features symposia and educational sessions on HSCT and cell therapy. More than 6,000 delegates attend the annual meeting, which continues to evolve with new topics added every year.
The RACE trial demonstrated that adding Eltrombopag to standard immunosuppressive treatment increases response rates in patients with Severe Aplastic Anaemia. The study found significant improvements in complete response rates, sustained at 6 months, and showed Eltrombopag was generally well-tolerated.
The eGVHD App is a user-friendly tool that supports accurate GvHD diagnosis and scoring after HCT. It provides guidelines, definitions, and pictures to help clinicians evaluate all potentially affected organ systems.
The new edition includes quality management, reflecting the rapidly evolving field of bone marrow transplantation. The standards have been developed through international consensus and are recognized globally among transplantation professionals.
The European Blood and Marrow Transplantation Textbook for Nurses has been released, providing comprehensive guidance on transplant nursing. The book aims to improve patient care by promoting training, education, and research in the field of hematopoietic stem cell transplantation (HSCT) and cellular therapy.
The RICMAC trial found that dose-reduced conditioning followed by allogeneic stem cell transplantation improved overall and relapse-free survival for patients with myelodysplastic syndrome. Engraftment rates were comparable between the two groups, with higher non-relapse mortality after standard conditioning.
Researchers have discovered that high doses of cyclophosphamide can selectively kill reactive immune cells, reducing the severity of graft-versus-host disease (GVHD) in patients. This breakthrough has paved the way for the use of mismatched donors in stem cell transplantation, improving access to treatment for many patients.
Cell therapy is an emerging medical science focusing on innovative therapeutic approaches to treat blood diseases and infections. The EBMT Cellular Therapy and Immunobiology Working Party aims to foster cellular therapy in Europe by promoting exchanges, cooperation, and the development of new technologies.
A record number of 40,829 hematopoietic stem cell transplantations (HSCT) were performed globally in 2014, with 36,469 patients treated. This represents a continued increase in HSCT rates, both allogeneic and autologous, over the past two decades.